Targeting the estrogen pathway for the treatment and prevention of lung cancer

Papers of special note have been highlighted as: ▪ of interest

References

• 1  American Cancer Society. Cancer Facts and Figures. American Cancer Society, GA, USA (2013).
  Google Scholar
• 2  Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J. Clin.63(1),11–30 (2013).
  MedlineGoogle Scholar
• 3  Traynor AM, Schiller JH, Stabile LP et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer64(1),51–59 (2009).▪ The first Phase I trial of antiestrogen therapy in combination with gefitinib was completed and demonstrated safety and potential efficacy.
  MedlineGoogle Scholar
• 4  Garon EB, Siegfried JM, Dubinett SM et al. Result of TORI L-03, a randomized, multicenter Phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).Presented at: AACR Annual Meeting 2013. Washington, DC, USA, 6–10 April 2013 (Abstract 4664).▪ The first Phase II trial of antiestrogen therapy with erlotinib in advanced non-small-cell lung cancer completed accrual and efficacy is observed.
  Google Scholar
• 5  Kreuzer M, Boffetta P, Whitley E et al. Gender differences in lung cancer risk by smoking: a multicentre case–control study in Germany and Italy. Br. J. Cancer82(1),227–233 (2000).
  Medline CASGoogle Scholar
• 6  Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int. J. Cancer54(1),44–48 (1993).
  Medline CASGoogle Scholar
• 7  Simonato L, Agudo A, Ahrens W et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int. J. Cancer91(6),876–887 (2001).
  Medline CASGoogle Scholar
• 8  Akiba S, Hirayama T. Cigarette smoking and cancer mortality risk in Japanese men and women – results from reanalysis of the six-prefecture cohort study data. Environ. Health Perspect.87,19–26 (1990).
  Medline CASGoogle Scholar
• 9  Bach PB, Kattan MW, Thornquist MD et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst.95(6),470–478 (2003).
  MedlineGoogle Scholar
• 10  Bain C, Feskanich D, Speizer FE et al. Lung cancer rates in men and women with comparable histories of smoking. J. Natl Cancer Inst.96(11),826–834 (2004).
  MedlineGoogle Scholar
• 11  Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol.9(7),649–656 (2008).
  MedlineGoogle Scholar
• 12  Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. Cancer Causes Control15(4),341–348 (2004).
  MedlineGoogle Scholar
• 13  Marang-Van De Mheen PJ, Smith GD, Hart CL, Hole DJ. Are women more sensitive to smoking than men? Findings from the Renfrew and Paisley study. Int. J. Epidemiol.30(4),787–792 (2001).
  Medline CASGoogle Scholar
• 14  Nilsson S, Carstensen JM, Pershagen G. Mortality among male and female smokers in Sweden: a 33 year follow up. J. Epidemiol. Community Health55(11),825–830 (2001).
  Medline CASGoogle Scholar
• 15  Prescott E, Osler M, Hein HO et al. Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population studies. Epidemiology9(1),79–83 (1998).
  Medline CASGoogle Scholar
• 16  Wakelee HA, Chang ET, Gomez SL et al. Lung cancer incidence in never smokers. J. Clin. Oncol.25(5),472–478 (2007).
  MedlineGoogle Scholar
• 17  Thun MJ, Hannan LM, Adams-Campbell LL et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med.5(9),e185 (2008).
  MedlineGoogle Scholar
• 18  Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA291(14),1763–1768 (2004).
  Medline CASGoogle Scholar
• 19  Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend. Med.7(5),381–401 (2010).
  MedlineGoogle Scholar
• 20  Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res.11(6),2106–2110 (2005).
  Medline CASGoogle Scholar
• 21  Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res.65(4),1459–1470 (2005).▪ First report of nongenomic estrogen receptor (ER) signaling and the connection between the ER and EGF receptor pathways.
  Medline CASGoogle Scholar
• 22  Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids72(2),135–143 (2007).
  Medline CASGoogle Scholar
• 23  Albain KS, Crowley JJ, Leblanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol.9(9),1618–1626 (1991).
  Medline CASGoogle Scholar
• 24  Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res.48(24 Pt 1),7279–7284 (1988).
  Medline CASGoogle Scholar
• 25  Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer44(5),833–839 (1989).▪ Hormone replacement therapy is found to be associated with increased lung cancer mortality.
  Medline CASGoogle Scholar
• 26  Taioli E, Wynder EL. Re: endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst.86(11),869–870 (1994).
  Medline CASGoogle Scholar
• 27  Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol.24(1),59–63 (2006).▪ Hormone replacement therapy is found to be associated with increased lung cancer mortality.
  Medline CASGoogle Scholar
• 28  Rodriguez C, Spencer Feigelson H, Deka A et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol. Biomarkers Prev.17(3),655–660 (2008).
  Medline CASGoogle Scholar
• 29  Mahabir S, Spitz MR, Barrera SL, Dong YQ, Eastham C, Forman MR. Dietary boron and hormone replacement therapy as risk factors for lung cancer in women. Am. J. Epidemiol.167(9),1070–1080 (2008).
  Medline CASGoogle Scholar
• 30  Schwartz AG, Wenzlaff AS, Prysak GM et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol.25(36),5785–5792 (2007).
  MedlineGoogle Scholar
• 31  Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case–control analysis. Clin. Cancer Res.10(1 Pt 1),113–123 (2004).
  Medline CASGoogle Scholar
• 32  Ramnath N, Menezes RJ, Loewen G et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case–control study. Oncology73(5–6),305–310 (2007).
  Medline CASGoogle Scholar
• 33  Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol.32(2),263–271 (2003).
  MedlineGoogle Scholar
• 34  Chlebowski RT, Schwartz AG, Wakelee H et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet374(9697),1243–1251 (2009).▪ Hormone replacement therapy is found to be associated with increased lung cancer mortality.
  Medline CASGoogle Scholar
• 35  Chlebowski RT, Anderson GL, Manson JE et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J. Natl Cancer Inst.102(18),1413–1421 (2010).
  MedlineGoogle Scholar
• 36  Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J. Clin. Oncol.28(9),1540–1546 (2010).
  MedlineGoogle Scholar
• 37  Bouchardy C, Benhamou S, Schaffar R et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer117(6),1288–1295 (2011).▪ Use of adjuvant antiestrogen therapy reduces the risk of lung cancer.
  MedlineGoogle Scholar
• 38  Lother SA, Harding GA, Musto G, Navaratnam S, Pitz MW. Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. Horm. Cancer4(5),270–276 (2013).
  Medline CASGoogle Scholar
• 39  Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res.62(7),2141–2150 (2002).▪ First description of high ERβ expression in the majority of non-small-cell lung cancer cases.
  Medline CASGoogle Scholar
• 40  Stabile LP, Dacic S, Land SR et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin. Cancer Res.17(1),154–164 (2011).▪ Demonstrated that ERβ is a poor prognostic marker in early non-small-cell lung cancer.
  Medline CASGoogle Scholar
• 41  Skov BG, Fischer BM, Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer59(1),88–94 (2008).
  MedlineGoogle Scholar
• 42  Schwartz AG, Prysak GM, Murphy V et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin. Cancer Res.11(20),7280–7287 (2005).
  Medline CASGoogle Scholar
• 43  Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg.130(4),979–986 (2005).
  Medline CASGoogle Scholar
• 44  Kawai H, Ishii A, Washiya K et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res.11(14),5084–5089 (2005).
  Medline CASGoogle Scholar
• 45  Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin. Cancer Res.15(17),5359–5368 (2009).
  Medline CASGoogle Scholar
• 46  Niikawa H, Suzuki T, Miki Y et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin. Cancer Res.14(14),4417–4426 (2008).
  Medline CASGoogle Scholar
• 47  Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in non-small cell lung cancer – a potent prognostic factor and possible target for endocrine therapy. Cancer Res.65(14),6450–6458 (2005).
  Medline CASGoogle Scholar
• 48  Mazieres J, Rouquette I, Lepage B et al. Specificities of lung adenocarcinoma in women who have never smoked. J. Thorac. Oncol.8(7),923–929 (2013).
  Medline CASGoogle Scholar
• 49  Patrone C, Cassel TN, Pettersson K et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol. Cell. Biol.23(23),8542–8552 (2003).
  Medline CASGoogle Scholar
• 50  Morani A, Barros RP, Imamov O et al. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta^-/-) mice. Proc. Natl Acad. Sci. USA103(18),7165–7169 (2006).
  Medline CASGoogle Scholar
• 51  Bogush TA, Dudko EA, Beme AA et al. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc.)75(12),1421–1427 (2010).
  Medline CASGoogle Scholar
• 52  Nose N, Sugio K, Oyama T et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J. Clin. Oncol.27(3),411–417 (2009).
  Medline CASGoogle Scholar
• 53  Navaratnam S, Skliris G, Qing G et al. Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Horm. Cancer3(3),93–100 (2012).
  Medline CASGoogle Scholar
• 54  Liu Z, Liao Y, Tang H, Chen G. The expression of estrogen receptors β2, 5 identifies and is associated with Prognosis in non-small cell lung cancer. Endocrine44(2),517–524 (2013).
  Medline CASGoogle Scholar
• 55  Weinberg OK, Marquez-Garban DC, Fishbein MC et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res.65(24),11287–11291 (2005).
  Medline CASGoogle Scholar
• 56  Mah V, Seligson DB, Li A et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res.67(21),10484–10490 (2007).
  Medline CASGoogle Scholar
• 57  Verma MK, Miki Y, Abe K et al. Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: gender-dependent clinical outcome. Life Sci.91(15–16),800–808 (2012).
  Medline CASGoogle Scholar
• 58  Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann. NY Acad. Sci.1155,194–205 (2009).
  Medline CASGoogle Scholar
• 59  Abe K, Miki Y, Ono K et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum. Pathol.41(2),190–198 (2010).
  Medline CASGoogle Scholar
• 60  Mah V, Marquez D, Alavi M et al. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer74(2),318–325 (2011).
  MedlineGoogle Scholar
• 61  Su JM, Hsu HK, Chang H et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res.16(6b),3803–3806 (1996).
  Medline CASGoogle Scholar
• 62  Kaiser U, Hofmann J, Schilli M et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer67(3),357–364 (1996).
  Medline CASGoogle Scholar
• 63  Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch. Pathol. Lab. Med.124(10),1467–1470 (2000).
  Medline CASGoogle Scholar
• 64  Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr. Relat. Cancer15(2),475–483 (2008).
  Medline CASGoogle Scholar
• 65  Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res.65(4),1598–1605 (2005).
  Medline CASGoogle Scholar
• 66  Hershberger PA, Stabile LP, Kanterewicz B et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J. Steroid Biochem. Mol. Biol.116(1–2),102–109 (2009).
  Medline CASGoogle Scholar
• 67  Garon EB, Pietras RJ, Finn RS et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J. Thorac. Oncol.8(3),270–278 (2013).
  Medline CASGoogle Scholar
• 68  Shen L, Li Z, Shen S et al. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Lung Cancer78(3),193–200 (2012).
  MedlineGoogle Scholar
• 69  Xu R, Shen H, Guo R, Sun J, Gao W, Shu Y. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomed. Pharmacother.66(5),384–389 (2012).
  Medline CASGoogle Scholar
• 70  Tang H, Liao Y, Xu L et al. Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int. J. Cancer133(10),2473–2482 (2013).
  Medline CASGoogle Scholar
• 71  Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J. Thorac. Oncol.7(3),485–495 (2012).
  Medline CASGoogle Scholar
• 72  Stabile LP, Rothstein ME, Cunningham DE et al. Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis33(11),2181–2189 (2012).▪ First demonstration that antiestrogens and aromatase inhibitors can prevent lung tumor formation in vivo.
  Medline CASGoogle Scholar
• 73  Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat. Rev.39(5),507–517 (2013).
  Medline CASGoogle Scholar
• 74  Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet2,, 104–107, 162–165 (1896).
  Google Scholar
• 75  Manni A, Arafah B, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer46(12 Suppl.),2838–2841 (1980).
  Medline CASGoogle Scholar
• 76  Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol. Rev.6(e15),122–129 (2012).
  Google Scholar
• 77  Miller WR, Bartlett J, Brodie AM et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist13(8),829–837 (2008).
  Medline CASGoogle Scholar
• 78  Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol.28(30),4594–4600 (2010).
  Medline CASGoogle Scholar
• 79  Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18),1371–1388 (1998).
  Medline CASGoogle Scholar
• 80  Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet360(9336),817–824 (2002).
  Medline CASGoogle Scholar
• 101  Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT01664754
  Google Scholar